Identification and characterization of multidrug-resistant Salmonella enterica serotype Albert isolates in the United States

Antimicrobial Agents and Chemotherapy
J P FolsterJean M Whichard

Abstract

Salmonella enterica is one of the most common causes of bacterial foodborne illness in the United States. Although most Salmonella infections are self-limiting, antimicrobial treatment of invasive salmonellosis is critical. The primary antimicrobial treatment options include fluoroquinolones or extended-spectrum cephalosporins, and resistance to these antimicrobial drugs may complicate treatment. At present, S. enterica is composed of more than 2,600 unique serotypes, which vary greatly in geographic prevalence, ecological niche, and the ability to cause human disease, and it is important to understand and mitigate the source of human infection, particularly when antimicrobial resistance is found. In this study, we identified and characterized 19 S. enterica serotype Albert isolates collected from food animals, retail meat, and humans in the United States during 2005 to 2013. All five isolates from nonhuman sources were obtained from turkeys or ground turkey, and epidemiologic data suggest poultry consumption or live-poultry exposure as the probable source of infection. S. enterica serotype Albert also appears to be geographically localized to the midwestern United States. All 19 isolates displayed multidrug resistance, includi...Continue Reading

References

Mar 1, 1994·The Journal of Infectious Diseases·B MishuR V Tauxe
Mar 31, 1998·Lancet·L Martínez-MartínezG A Jacoby
Feb 15, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E L Hohmann
Dec 10, 2003·Journal of Clinical Microbiology·S ZhaoR D Walker
Jan 9, 2004·Applied and Environmental Microbiology·Sheng ChenJianghong Meng
Jan 19, 2005·The Journal of Infectious Diseases·Jay K VarmaFrederick J Angulo
Jun 7, 2005·Journal of Microbiological Methods·Alessandra CarattoliE John Threlfall
Mar 22, 2007·PloS One·Timothy J WelchJacques Ravel
Dec 13, 2007·CJEM·Clinton T Forsythe, Michael E Ernst
Feb 3, 2009·Applied and Environmental Microbiology·Rebecca L LindseyRichard J Meinersmann
Jun 2, 2009·Journal of Bacteriology·W Florian FrickeJacques Ravel
Nov 6, 2009·The Journal of Veterinary Medical Science·Akemi KojimaToshio Takahashi
Aug 20, 2010·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN U.S. Food And Drug Administration
Oct 12, 2010·Journal of Bacteriology·Vartul SangalMark Achtman
Jan 5, 2011·Antimicrobial Agents and Chemotherapy·John A CrumpUNKNOWN Emerging Infections Program NARMS Working Group
Sep 3, 2011·Foodborne Pathogens and Disease·Jason P FolsterJean M Whichard
Mar 28, 2012·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN Centers for Disease Control and Prevention, Public Health Service, U.S. Department Health
May 25, 2012·AJR. American Journal of Roentgenology·Tiffany HennedigeSudhakar K Venkatesh
Jul 24, 2013·Emerging Infectious Diseases·Brendan R JacksonShua J Chai

❮ Previous
Next ❯

Citations

Oct 18, 2016·Frontiers in Microbiology·Wenyao ChenChunlei Shi
Nov 26, 2016·Expert Review of Anti-infective Therapy·Susan ZelaskoKrystyna Dabrowska
Apr 4, 2019·Journal of Water and Health·Kevin WelchShelley Zansky

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.